AlosetronHydrochloride , 2mMinWater , 122852-69-1

Synonym(s):
2,3,4,5-Tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one hydrochloride

CAS NO.：122852-69-1

Empirical Formula: C17H19ClN4O

Molecular Weight: 330.81

MDL number: MFCD03453647

EINECS: 802-450-0

PRODUCT Properties

• Melting point: 288-291°C
• storage temp.: 2-8°C
• solubility: H2O: ≥5mg/mL at warmed
• form: powder
• color: white to beige

Description and Uses

Lotronex (alosetron) was developed for the treatment of severe irritable bowel syndrome (IBS), and was approved for use by the US Food and Drug Administration (FDA) in 2000. Although Lotronex had a relatively high improvement rate in patients taking the drug for IBS, it was voluntarily pulled from the market by GlaxoWellcome that same year due to reports of severe adverse side effects, some resulting in death.
In 2002, Lotronex was reapproved in a supplemental New Drug Application for use under more restrictive conditions. Now with a risk management program to be consulted prior to administration of the drug, Lotronex is designated to be prescribed only when its medical benefits outweigh the risks of toxic effects; women with severe diarrhea-predominant IBS are now the focal point of prescriptions for Lotronex.

Lotronex is used for severe diarrhea-predominant IBS in women. There are other potential uses, as animal models have shown at least some evidence for the ability of Lotronex to mitigate the effects of psychosis, anxiety, cognitive impairment, emesis, and drug withdrawal. These possibilities have not been verified in humans, however.

Safety

• Symbol(GHS): GHS06
• Signal word: Danger
• Hazard statements: H301-H319-H412
• Precautionary statements: P273-P301+P310+P330-P305+P351+P338
• Hazard Codes: T,Xi
• Risk Statements: 25-36-52/53
• Safety Statements: 26-45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• HS Code: 2933790002